Roivant Sciences Ltd.
ROIV
Rang in aandelen
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Aandeelprijs
$33.73
Laatst gesynchroniseerd: 2026-07-31
Marktkapitalisatie
$24.37B
Verandering (1 dag)
-2.28%
Verandering (1 jaar)
90.15%
Land
GB
Handel Roivant Sciences Ltd. (ROIV)
Categorie
Healthcare
P/B-ratio voor Roivant Sciences Ltd. (ROIV)
P/B-ratio op October 2026 TTM: 5.73
Volgens de meest recente financiële rapporten en aandelenkoers van Roivant Sciences Ltd. is de huidige P/B-ratio (TTM) 5.73. Eind 2024 had het bedrijf een P/B-ratio van 1.37.
P/B-ratiohistoriek voor Roivant Sciences Ltd. van 2020 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 5.73 | 267.12% |
| 2025 | 1.56 | 14.08% |
| 2024 | 1.37 | -69.88% |
| 2023 | 4.54 | 127.54% |
| 2022 | 2.00 | -46.40% |
| 2021 | 3.73 | 6.30% |
| 2020 | 3.50 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 9.15% |
US
|
|
| 13.2547 | 131.44% |
US
|
|
| 4.208 | -26.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 7.95% |
NL
|
